Switzerland Approves Study Examining Effects of Controlled Purchases of Cannabis
The study will examine consumption and health of the participants after purchasing selected cannabis products from controlled cultivation under regulated conditions.
On March 21, 2023, the study titled “Züri Can–Cannabis with responsibility,” created by the City of Zurich and the University of Zurich, met approval and opened its registration process, after being postponed in 2022. “The study examines the effects of purchasing selected cannabis products from controlled cultivation under regulated conditions on the consumption and health of the participants,” read the study, translated from German (1). “In addition, different models of regulated cannabis procurement are to be compared with one another.”
The sale of cannabis products for the study will begin at the preestablished supply points after the summer holidays, and only organic and local products will be permitted (1). Currently, cannabis products containing less than 1% THC are permitted in Switzerland under limited instances (2).
“As a study participant, you will contribute to research into a possible regulation of cannabis consumption in Switzerland,” read the consent form in part, translated from German (3). “If you meet the eligibility requirements below and are included in the study, you can legally purchase cannabis for personal use for three years under regulated conditions. As a study participant, you must fill out a scientific online questionnaire at regular intervals.”
Scientific, approved pilot trials of controlled sales of cannabis for recreational purposes were first allowed in 2021 (4). Future studies with public and university sponsors are planned for several more cities in Switzerland (1).
References
- https://www.stadt-zuerich.ch/portal/de/index/politik_u_recht/stadtrat/weitere-politikfelder/drogen-suchtpolitik/studien-und-projekte/cannabisprojekt-der-stadt-zuerich/wissenswertes-zur-cannabis-studie.html
- https://www.ch.ch/en/health/medicines-and-narcotic-substances/cannabis/#when-is-cannabis-an-illegal-drug
- https://www.stadt-zuerich.ch/portal/de/index/politik_u_recht/stadtrat/weitere-politikfelder/drogen-suchtpolitik/studien-und-projekte/cannabisprojekt-der-stadt-zuerich/konsumierende.html
- https://www.stadt-zuerich.ch/portal/de/index/politik_u_recht/stadtrat/weitere-politikfelder/drogen-suchtpolitik/studien-und-projekte/cannabisprojekt-der-stadt-zuerich.html#
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
